Human multidrug resistance-1 gene expression levels in graves-basedow disease
S Cetinkalp1, M Karadeniz, M Erdoğan
1Department of Endocrinology and Metabolism, Ege University Medical School, Izmir, Turkey.
Summary
Multidrug resistance 1 (MDR-1) gene expression in Graves' disease patients correlates with disease activity and treatment resistance. Higher MDR-1 levels are linked to longer euthyroid periods, suggesting a role in managing hyperthyroidism.
Area of Science:
- Endocrinology
- Molecular Biology
- Genetics
Background:
- Multidrug resistance 1 (MDR-1) gene influences drug resistance in human cells.
- Thyroid stimulant hormone receptor (TSH-R) antibody positivity characterizes Graves' disease.
Purpose of the Study:
- To evaluate MDR-1 gene expression in subjects with TSH-R antibody positive Graves' disease.
- To investigate the correlation between MDR-1 expression and clinical parameters in Graves' disease.
Main Methods:
- Enrolled 33 hyperthyroid subjects (23 female, 10 male) treated with propylthiouracil (PTU).
- Collected blood samples pre-treatment to assess MDR-1 gene expression.
- Measured serum hormone levels (F-T3, F-T4, TSH) and TSH-R antibody levels.
Main Results:
- Graves' subjects exhibited high F-T3/F-T4 and low TSH levels.
- MDR-1 gene expression decreased with increasing age in Graves' patients.
- Positive correlations were observed between MDR-1 expression and TSH-R Ab levels, thyroid gland size, and duration of euthyroid state.
Conclusions:
- Elevated blood MDR-1 gene expression in Graves'-Basedow disease may indicate disease activity and treatment resistance.
- Increased MDR-1 expression is associated with a prolonged euthyroid state, suggesting a potential role in disease management.
Related Concept Videos
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...